

Application No. 09/509,165

Docket No. 27866/34810

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-25. (canceled)

26. (currently amended) A method of palliating an allergic reaction in a mammalian subject, comprising the steps of:

identifying a mammalian subject in need of treatment for an allergic reaction that is characterized by eosinophil accumulation, and

administering to said mammalian subject a composition comprising an MDC antagonist compound in an amount effective to palliate the allergic reaction; reaction; wherein the MDC antagonist comprises an antibody substance that specifically binds to a vertebrate MDC polypeptide.

27-29. (canceled)

30. (currently amended) A method according to claim 26 wherein the MDC antagonist compound is selected from the group consisting of:

(a) an antibody that specifically binds a vertebrate MDC polypeptide;

(b) a polypeptide that specifically binds a vertebrate MDC polypeptide and comprises an antigen-binding fragment of an anti-MDC antibody; and

(e) a polypeptide comprising the C-C chemokine receptor 4 (CCR4) amino acid sequence set forth in SEQ ID NO: 34 or comprising a continuous fragment thereof that specifically binds MDC; and

[[(d)]] (c) combinations of (a)-(e); (a) and (b).

31. (currently amended) A method according to claim 26 wherein said MDC antagonist compound comprises an antibody substance that binds MDC, said antibody substance is selected from the group consisting of monoclonal antibodies, polyclonal

Application No. 09/509,165

Docket No. 27866/34810

antibodies, single chain [[cell]] antibodies, chimeric, chimeric antibodies, and humanized antibodies.

32-37. (canceled)

38. (currently amended) The method according to claim 26 wherein the MDC antagonist compound is a monoclonal antibody selected from the group consisting of 191D, 252Y and 252Z antibody.

39. (previously presented) The method according to claim 26, wherein the MDC antagonist compound is a polypeptide that specifically binds a vertebrate MDC polypeptide and comprises an antigen-binding fragment of an anti-MDC antibody.

40-41. (canceled)

42. (currently amended) A method of palliating an allergic reaction in a mammalian subject, comprising the steps of:

identifying a mammalian subject in need of treatment for an allergic reaction that is characterized by eosinophil accumulation, and

administering to said mammalian subject a composition comprising a TARC antagonist compound in an amount effective to palliate the allergic reaction, reaction; wherein the TARC antagonist comprises an antibody substance that specifically binds to a vertebrate TARC polypeptide.

43. (currently amended) A method according to claim 42 wherein the TARC antagonist compound is selected from the group consisting of:

- (a) an antibody that specifically binds a vertebrate TARC polypeptide;
- (b) a polypeptide that specifically binds a vertebrate TARC polypeptide and comprises an antigen-binding fragment of an anti-TARC antibody; and

Application No. 09/509,165

Docket No. 27866/34810

(c) a polypeptide comprising the C-C chemokine receptor 4 (CCR4) amino acid sequence set forth in SEQ ID NO: 34 or comprising a continuous fragment thereof that specifically binds TARC; and

[(d)] (c) combinations of (a)-(e), (a) and (b).

44. (new) The method according to claim 42 wherein said antibody substance is selected from the group consisting of monoclonal antibodies, polyclonal antibodies, single chain antibodies, chimeric antibodies, and humanized antibodies.

45. (new) The method according to claim 42, wherein said TARC antagonist is a monoclonal antibody.

46. (new) The method according to claim 42, wherein the TARC antagonist compound is a polypeptide that specifically binds a vertebrate TARC polypeptide and comprises an antigen-binding fragment of an anti-TARC antibody.

47. (new) The method according to claim 38, wherein the monoclonal antibody is selected from the group consisting of 191D (produced by a hybridoma with ATCC Accession No. HB-12122), 252Y (produced by a hybridoma with ATCC Accession No. HB-12433), 252Z (produced by a hybridoma with ATCC Accession No. HB-12434), and 272D (produced by a hybridoma with ATCC Accession No. HB-12498).

48. (new) The method according to claim 26, wherein the antibody substance specifically binds to a human MDC polypeptide.

49. (new) The method according to claim 26, wherein the antibody substance is a humanized antibody.

Application No. 09/509,165

Docket No. 27866/34810

50. (new) The method according to claim 42, wherein the antibody substance specifically binds to a human TARC polypeptide.

51. (new) The method according to claim 42, wherein the antibody substance is a humanized antibody.

52. (new) The method according to claim 26, further comprising administering a TARC antagonist compound, wherein the MDC antagonist compound and the TARC antagonist compound are administered in amounts effective to palliate the allergic reaction, and wherein the MDC antagonist compound and the TARC antagonist compound comprise antibody substances that specifically bind to a vertebrate MDC polypeptide and a TARC polypeptide respectively.

53. (new) The method according to claim 52, wherein the antibody substances bind to a human MDC polypeptide and human TARC polypeptide respectively.

54. (new) The method according to claim 52, wherein the antibody substances are humanized antibodies.